Quadrant Capital Group LLC boosted its stake in Eli Lilly and Co. (NYSE:LLY) by 34.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,437 shares of the company’s stock after buying an additional 874 shares during the period. Quadrant Capital Group LLC’s holdings in Eli Lilly and were worth $258,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Renaissance Technologies LLC raised its position in Eli Lilly and by 565.1% in the first quarter. Renaissance Technologies LLC now owns 2,213,605 shares of the company’s stock valued at $159,402,000 after buying an additional 1,880,800 shares during the last quarter. Beutel Goodman & Co Ltd. purchased a new position in Eli Lilly and during the second quarter valued at about $104,345,000. Bank of Montreal Can purchased a new position in Eli Lilly and during the second quarter valued at about $86,545,000. Franklin Resources Inc. raised its position in Eli Lilly and by 3.6% in the first quarter. Franklin Resources Inc. now owns 27,744,978 shares of the company’s stock valued at $1,997,920,000 after buying an additional 961,204 shares during the last quarter. Finally, NN Investment Partners Holdings N.V. purchased a new position in Eli Lilly and during the first quarter valued at about $61,280,000. Hedge funds and other institutional investors own 74.96% of the company’s stock.
Shares of Eli Lilly and Co. (NYSE:LLY) traded up 0.76% during midday trading on Friday, reaching $82.09. The company had a trading volume of 4,241,408 shares. Eli Lilly and Co. has a 12-month low of $67.88 and a 12-month high of $88.16. The firm has a market capitalization of $86.83 billion, a price-to-earnings ratio of 35.38 and a beta of 0.17. The company has a 50 day moving average of $79.37 and a 200 day moving average of $77.41.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Tuesday, July 26th. The company reported $0.86 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.86. The business earned $5.40 billion during the quarter, compared to the consensus estimate of $5.14 billion. Eli Lilly and had a return on equity of 23.99% and a net margin of 11.97%. The firm’s quarterly revenue was up 8.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.90 earnings per share. Analysts anticipate that Eli Lilly and Co. will post $3.59 EPS for the current year.
Several research firms have recently weighed in on LLY. Jefferies Group lifted their price objective on shares of Eli Lilly and from $100.00 to $105.00 and gave the company a “buy” rating in a research note on Thursday, July 14th. Goldman Sachs Group Inc. upgraded shares of Eli Lilly and from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $89.00 to $95.00 in a research note on Tuesday, September 27th. Zacks Investment Research lowered shares of Eli Lilly and from a “buy” rating to a “hold” rating in a research note on Thursday, August 4th. Argus lifted their price objective on shares of Eli Lilly and from $90.00 to $95.00 and gave the company a “buy” rating in a research note on Tuesday, August 2nd. Finally, JPMorgan Chase & Co. upgraded shares of Eli Lilly and from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $92.00 to $95.00 in a research note on Thursday, September 8th. Three equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. Eli Lilly and currently has an average rating of “Buy” and an average target price of $97.16.
In other news, major shareholder Lilly Endowment Inc sold 210,000 shares of the firm’s stock in a transaction on Tuesday, July 12th. The stock was sold at an average price of $79.54, for a total transaction of $16,703,400.00. Following the completion of the transaction, the insider now directly owns 126,220,804 shares in the company, valued at $10,039,602,750.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Maria A. Crowe sold 2,248 shares of the firm’s stock in a transaction on Wednesday, October 5th. The shares were sold at an average price of $81.37, for a total value of $182,919.76. Following the transaction, the insider now owns 94,319 shares of the company’s stock, valued at $7,674,737.03. The disclosure for this sale can be found here. 0.20% of the stock is owned by company insiders.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co. (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co. and related companies with MarketBeat.com's FREE daily email newsletter.